Biomarin Pharmaceutical (BMRN) Net Cash Flow Growth (3y) (2012 - 2026)
Biomarin Pharmaceutical (BMRN) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | 141.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 141.93% |
| Dec 31, 2025 | 53.67% |
| Sep 30, 2025 | -37.04% |
| Jun 30, 2025 | 125.04% |
| Mar 31, 2025 | 84.59% |
| Dec 31, 2024 | 121.56% |
| Sep 30, 2024 | -131.06% |
| Jun 30, 2024 | 118.03% |
| Mar 31, 2024 | -36.58% |
| Dec 31, 2023 | 58.34% |
| Sep 30, 2023 | -23.14% |
| Jun 30, 2023 | -31.21% |
| Mar 31, 2023 | -75.45% |
| Dec 31, 2022 | -70.62% |
| Sep 30, 2022 | 6.84% |
| Jun 30, 2022 | 31.26% |
| Mar 31, 2022 | 28.68% |
| Dec 31, 2021 | 57.47% |
| Sep 30, 2021 | -27.08% |
| Jun 30, 2021 | 16.87% |